Candel Therapeutics, Inc.

Healthcare

NASDAQ:CADL · NASDAQ Global Market

Market Cap $456.23M Beta -0.48 P/E (TTM) -9.2

$8.31 +0.56%

+$0.05 today

52W Low $4.35High $9.57

Vol 5.53M · Avg 1.82M

EPS (TTM) -$0.87Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+77.94%

Period High

$9.27

Period Low

$4.42

Latest

$8.31

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Capricor Therapeutics, Inc.

NASDAQ:CAPR

$1.29B

Cabaletta Bio, Inc.

NASDAQ:CABA

$467.15M

Contineum Therapeutics, Inc. Class A Common Stock

NASDAQ:CTNM

$439.66M

Kyverna Therapeutics, Inc.

NASDAQ:KYTX

$349.24M

Editas Medicine, Inc.

NASDAQ:EDIT

$251.97M

ProQR Therapeutics N.V.

NASDAQ:PRQR

$193.86M

Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

$117.02M

Genelux Corporation

NASDAQ:GNLX

$109.47M

Immutep Limited

NASDAQ:IMMP

$55.40M

Mereo BioPharma Group plc

NASDAQ:MREO

$50.66M

What is the latest CADL filing?

The latest filing shown is 8-K dated Jun 16, 2026.

How many recent filings does CADL have?

Intrinsic Alpha currently shows 20 recent filings for CADL.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.